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Essentials: 
 We estimated the cardiovascular risk of patients 
withMortality is higher in the Idiopathic 
Thrombocytopenic Purpura (ITP) cohort than the 
general population 
 This study is a retrospective cohort study using ‘The 
Health Improvement Network’a primary care database 
 The risk of cardiovascular disease was 38% higher in 
ITP patients compared to patients without ITP 
 appears to be higher in the ITP cohortAmong the ITP 
patients, splenectomy was associated with higher 
cardiovascular disease 
 Clinicians should consider cardiovascular risk when 
managing ITP patients and when considering 
splenectomy 
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Abstract: 
 
Background: Idiopathic Thrombocytopenic Purpura (ITP) is 
classically characterized by a transient or persistent decrease of 
platelet count. Mortality is higher in the ITP population than 
the general population, with a possible association to increased 
cardiovascular disease (CVD).   
Objectives: The objective was to assess the strength of the 
association between ITP and CVD, with a secondary aim to 
assess the impact of splenectomy on CVD. 
Methods: A population-based retrospective, open cohort study 
using clinical codes was performed using data from 6,591 
patients with ITP and 24,275 randomly matched controls (up to 
1:4 ratio matched by age, sex, body mass index and smoking 
status). The main outcome was the risk of CVD which included 
ischemic heart disease, stroke, trans-ischemic attack and heart 
failure. Adjusted incidence rate ratios were calculated using 
Poisson regression.  
Results:  During a median 6-year observation period there was 
a CVD diagnosis recorded in 392 (5·9%) of ITP patients and 
1,114 (4·5%) of control patients. There was an increased risk of 
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developing CVD in the ITP cohort (adjusted IRR 1·38; CI 95% 
1·23-1.55), which remained robust even after a sensitivity 
analysis only including incident cases of ITP. Findings 
suggested that patients who have undergone splenectomy were 
at even further increased risk of developing CVD when 
comparing to the ITP population who had not undergone 
splenectomy (adjusted IRR 1·69; CI 95% 1·22-2·34). 
Conclusion: There is an increased risk of developing CVD in 
patients with ITP and even further increased risk for those 
patients with ITP who underwent splenectomy.  
 
Keywords: 
Purpura, Thrombocytopenic, Idiopathic  
Blood platelet disorders 
Thrombocytopenia 
Retrospective Studies 
Cardiovascular Diseases 
 
 
 
Introduction: 
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Idiopathic Thrombocytopenic Purpura (ITP) is an acquired 
immune-mediated disease defined as a transient or persistent 
decrease of platelet count.[1,2] The decreased platelet count in 
ITP is associated with an increased rate of bleeding, 
hemorrhage related outcomes[3] and abnormal platelet 
activity.[4] Global incidence rate for ITP in adults are 
estimated to be 1·6-3·9/100,000 persons with prevalence rates 
estimated at 5·6-20/100,000 population.[5] Prevalence reported 
in UK is particularly high with an estimated incidence of 3· 
9/100,000 persons and a prevalence of 50/100,000 
population.[6,7]  
 
It has been well established that mortality is higher within the 
ITP cohort than the general population.[8,9] Previous 
population based studies have also identified a comparatively 
higher incidence of diabetes, acute/chronic renal failure, 
leukemia, and Hodgkin’s disease within the ITP cohort.[8] An 
increased incidence in any vascular event (IRR 1·0 95% CI 
1·41-2·05) and particularly unstable angina, ischemic stroke 
and TIA have been identified in a cohort study conducted in the 
United States utilizing insurance data.[8] However there has 
been conflicting evidence surrounding the nature and strength 
of the association between myocardial infarction (MI) and 
ITP.[8,10]  The only study conducted in UK looked at multiple 
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conditions and did not account for the time to event or adjust 
for important confounders.[10] 
 
The pathophysiology by which ITP affects cardiovascular 
disease is unclear. Platelet destruction releases humoral factors 
and platelet micro-particles (PMPs)[11] which are elevated in 
ITP patients.[12] PMPs induce thrombin and coagulation 
activations, which may increase thrombotic outcomes.[13] ITP 
patients often have elevated pro-inflammatory cytokines 
suggesting an inflammatory etiology.[14,15] Inflammatory 
activity may also affect coagulation states which could put 
individuals at risk of thrombotic events.[16] 
 
The mainstay of treatment for ITP (based on severity deemed 
by platelet count) is the use of glucocorticosteroids. The 
majority of ITP cases are steroid-responsive and total remission 
can be achieved in 33% of cases.[17] Partial or total 
splenectomy is an alternative treatment for adult patients not 
responding to glucocorticoid therapy with remission of ITP in 
two-thirds of cases.[18] Splenectomy is not without risk, and 
even the laparoscopic approach bears significant risk of 
surgical complications (9.6%).[18] It has been identified that 
ITP patients who undergo splenectomy are at a higher risk of 
venous thromboembolic events.[19] The pathophysiological 
link is unclear. There is evidence to suggest that splenectomy 
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may lead to both thrombocytosis and an increased number of 
damaged red cells. This induces a hypercoagulable state with 
increase thrombotic risk.[20–22] Post-splenectomy patients 
have been shown to have even higher levels of cellular micro-
particles (C-MPs) which further promotes 
hypercoagulability.[23] 
 
This study aims to explore the association between ITP and 
cardio-vascular disease as well as attempt to identify the impact 
of splenectomy on this association.  
Methods: 
 
Study Design:  
 
A population based, retrospective open cohort study in which 
patients diagnosed with ITP were compared to healthy controls 
matched by age, sex, body mass index (BMI) and smoking 
status. The Health Improvement Network (THIN) has been 
demonstrated to be broadly representative of the U.K. 
population.[24] 
 
Data Source:  
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The THIN database comprises of UK electronically recorded 
medical records in primary care, with the purpose of the 
database to encourage research in order to improve health care 
delivery. The THIN database comprises of 675 UK general 
practices, compiling data of over 14 million patients, of which 
over approximately 3.6 million who are actively registered 
broadly representative of the UK population.[25] Patient 
information is entered into Vision patient record software 
which uses Read code data (Clinical code)[26], rather than the 
International Classification of Diseases (ICD) codes. The 
Vision software also captures laboratory results as well as some 
British National Formulary Drug prescription records.[27] The 
University of Birmingham holds a data sharing agreement with 
IMSHealth (the providers of THIN) to allow for data to be used 
for research under the Data Protection Act (1998). [28] 
 
Study Population: 
 
The study population consisted of patients diagnosed with ITP 
(exposed) and controls not diagnosed with ITP (unexposed) 
during the study period from 1st of January 1996 to the 1st of 
September 2015.  
 
Individual practices were eligible for inclusion in the study 
from the later of the following two dates to ensure that the 
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practice was making full use of their system and not under-
recording important outcomes: one year after the date their 
practice system was installed; and the practice’s acceptable 
mortality recording (AMR) date. Individual patients will be 
eligible for inclusion from the latest of the following dates to 
ensure that there was sufficient time for baseline data on 
comorbidities to have been recorded; the date their practice 
became eligible for inclusion; and a year after registration with 
their practice to allow for the recording of comorbidities.  
 
 
 
Selection Criteria:  
 
Follow-up start date for an indexed patient (index date) in the 
exposed group was set at first documentation of ITP once a 
patient was eligible to take part in the study (newly diagnosed 
patients/incident cases) or the date a patient became eligible to 
take part in the study, if they already have a diagnosis of ITP 
(patients with an existing diagnosis/prevalent cases) (Appendix 
1).  The same index date was assigned for their matched 
corresponding unexposed patients to mitigate immortality time 
bias. Both the exposed group (ITP) and unexposed group 
(control) were followed up from the index date until the first of 
the following events (exit date): patient died; patient left 
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practice; last data collection from practice; study end date; 
patient diagnosed with cardiovascular disease (stroke or 
ischemic heart disease, myocardial infarction and angina).  
 
Patients were excluded from the study if they had a diagnosis 
of CVD prior to the index date of the study. Individuals were 
included in the exposed group if they had a recorded diagnosis 
of ITP (Appendix 2) using clinical codes 
(https://digital.nhs.uk/article/1104/Read-Codes). ITP codes 
were validated from previous studies where read codes were 
used to identify exposed ITP patients.[29,30] In the U.K, the 
diagnosis of ITP is made by a hematologist in a 
secondary/tertiary setting which is then relayed to the GP, 
whose responsibility it would be to record this on the patient’s 
electronic medical record. The diagnostic criteria for 
identifying ITP in the UK secondary care setting is based on 
the “British Committee for Standards in Hematology” 
guideline. [31] A record of splenectomy also identified through 
clinical codes (Appendix 2) was also recorded at this point. 
Each ITP patient was then matched to 4 control patients in the 
unexposed cohort and were randomly selected from the same 
General Practice. Controls were individually matched to cases 
on age at index date (to within 2 years), BMI (to within 2 
Kg/m2), smoking status and gender. 
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Outcomes: 
 
The primary outcome was the development of a large vessel 
atherosclerotic/thrombotic cardiovascular event (Ischemic heart 
disease, heart failure and Stroke/TIA during the observation 
period as well as a composite outcome of all three) identified 
through clinical codes (Appendix 4). Recording of CVD is  
accurate in UK primary care because there is a mandatory 
requirement for maintaining a register for cardiovascular 
disease and incentive payments are made for identification and 
management of CVD [32].  
Co-Variates: 
 
Well known co-variates which impact on the development of 
cardiovascular disease were identified in the study population 
baseline data. These included hypertension, diabetes mellitus, 
inherited thrombophilias, co-morbidity identified through the 
Charlson co-morbidity index, the use of lipid lowering 
medications, anti-platelet agent medications and warfarin 
medications that were identified through clinical codes inputted 
by GPs in primary care (Appendix 3). 
 
Statistical analysis plan: 
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Baseline characteristics were descriptively compared between 
the groups. Comparison was assessed either using chi –squared 
(sex, Townsend deprivation score, smoking status, 
hypertension, diabetes mellitus, inherited thrombophilias, 
Charlson co-morbidity index, the use of lipid lowering 
medications, anti-platelet agent medications, warfarin 
medications), student t-test (age and BMI) or Mann-Whitney U 
test (person years).  
 
An estimated incidence rate ratio was calculated for each 
outcome. Then adjusted incidence rate ratios were calculated 
using Poisson regression adjusting for individual patient 
covariates (age, sex, Townsend deprivation score, smoking 
status, hypertension, diabetes mellitus, inherited 
thrombophilias, Charlson co-morbidity index, the use of lipid 
lowering medications, anti-platelet agent medications, warfarin 
medications to account for any variation in consultation 
practice). BMI was treated as a categorical variable to address 
missing values. Incidence rate ratios were calculated with 95% 
confidence and a statistical significance threshold of p<0·05. 
 
As a secondary analysis, we also assessed the impact of 
splenectomy on patient outcomes. We looked at the risk of 
cardiovascular disease within the ITP patients stratified by 
those who had splenectomy and those who did not. This 
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allowed for analysis of the isolated impact of splenectomy in 
the exposed group. 
 
In a sensitivity analysis, we restricted the investigation of 
occurrence of cardiovascular disease to only patients with 
incident diagnoses of ITP and their respective matched controls 
during the study period to account for survival bias that may 
underestimate or overestimate the effect size. 
 
All analysis was conducted using Stata v14.0 software. The 
THIN data collection scheme received multi-center research 
ethics committee (MREC) approval in 2003 with scientific 
committee approval of this particular study in March 2017 
(SRC 17THIN024) from ‘IMSHealth’ (data provider). 
 
Role of the funding source: 
 
There is no funding source to declare in this study. 
Results: 
 
Baseline Characteristics: 
 
A total of 6,591 patients with ITP were identified on the THIN 
database and matched to 24,275 controls (on 1:4 ratio). The 
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mean length of follow up in the ITP and control population, 
was 5.6 years (SD 4.5 years) and 6 years (SD 4·6 years) 
respectively. 
Mean patient age within the ITP cohort was 48.4 years (SD 
19·1 years) with significantly more females than males (58·6% 
vs. 41·3% respectively). In general, there was a significant 
difference in the proportion of patients with diabetes and lipid 
lowering medications between the ITP and control cohort. 
Baseline characteristics are described in further detail in Table 
1 (Missing values are in appendix 7). In the ITP group, there 
were 506 (7·6%) patients with splenectomy at study entry and 
an additional 162 splenectomies (in total 668;10·1%) during 
follow-up period. Three hundred and fifty-three (5·4%) patients 
were on active treatment with steroids at baseline. 
 
 
 
Association between cardiovascular disease and ITP: 
 
During the observation period 392 (5·9%) and 1,114 (4·5%) 
patients in the ITP and control groups respectively experienced 
cardiovascular event. The incidence rate was 11 and 8 per 1000 
person years respectively. The adjusted incidence rate ratio of 
all cardiovascular disease was found to be significantly higher 
in the ITP cohort compared to the control cohort (adjusted IRR 
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1·38; CI 95% 1·23-1.55, P<0.001). Further sub-analysis was 
carried out to compare the incidence of Ischemic heart disease, 
stroke/TIA, and heart failure separately in these cohorts. 
Following sub-analysis, the ITP cohort demonstrated increased 
adjusted incidence rate ratios of Ischemic heart disease (IRR 
1·21; CI 95% 1·01-1·44, P=0.034), Stroke or TIA (IRR 1·39; 
CI 95% 1·17-1·66, P<0.001) and heart failure or left 
ventricular dysfunction (IRR 1·42; CI 95% 1·12-1·81, 
P=0.004). (Table 2).
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The impact of splenectomy on cardiovascular disease in 
the ITP cohort: 
 
ITP patients with splenectomy at baseline had an increased 
adjusted (Adjusted for age, sex, Townsend deprivation score, 
smoking status, hypertension, diabetes mellitus and the use of 
lipid lowering medications, steroid use, Charlson co-morbidity 
index, anti-platelets, inherited thrombophilias, and warfarin 
use) incidence rate ratio of cardiovascular disease compared to 
ITP patients who did not have splenectomy (adjusted IRR 1·69; 
CI 95% 1·22-2·34, P=0·001). Active steroid treatment at 
baseline also had an increased incidence rate ratio for 
cardiovascular disease compared to ITP patients who did not 
have steroid treatment (adjusted IRR 1·49; CI 95% 1·07-2·08, 
P=0·017). 
 
Additional Analysis 
Results of an analysis also adjusting for consultation rate 
showed similar results (appendix 5), with an adjusted incidence 
rate ratio for cardiovascular disease significantly greater in ITP 
patient (1·49; CI 95% 1·33-1·67). An analysis restricted to 
incident ITP patients also showed concurrent results (appendix 
6). The adjusted incidence rate ratio for cardiovascular disease 
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was significantly greater in ITP patients compared to controls 
in incident only cases (1·38; CI 95% 1·15-1·66).  
 
Discussion:  
 
Summary of Key Results: 
 
This study found that individuals with ITP were at a higher risk 
of developing all types of CVD (adjusted IRR 1·38; CI 95% 
1·23-1.55, P<0.001). when compared to individuals without 
ITP over the observation period. These findings remained once 
adjusted for clinically significant risk factors for developing 
CVD. We also demonstrated that patients who have undergone 
splenectomy were at even further increased risk of developing 
CVD when comparing to the ITP population at baseline who 
had not undergone splenectomy (adjusted IRR 1·69; CI 95% 
1·22-2·34, P=0·001). 
  
Compared to Current Literature: 
 
The results of this study builds on the current literature 
surrounding ITP and CVD risk. ITP is an autoimmune 
condition characterized by a low platelet count and bleeding, 
but conversely individuals with ITP may show an increased 
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thrombotic and atherosclerotic risk[33] hypothesized to be due 
to PMP cascade. An American epidemiological study has 
demonstrated some of the significant associations between; ITP 
and TIA (IRR 1·69; CI 95% 1·21-2·35), ITP and stroke (IRR 
2·05; CI 95% 1·26-3·36) and insignificant association between 
ITP and MI (IRR 0.80; CI 95% 0.49-1.30).[8] Whereas General 
Practice Research Database (GPRD) data from the U.K. has 
previously shown a significantly positive association between 
ITP and; MI (OR 4·71; CI 95% 2·21-10·06), left ventricular 
failure (OR 2·94; CI 95% 1·43-6·06) and cerebrovascular 
accident (OR 2·30; CI 95% 1·21-4·38).[10] The results of this 
study are confirmatory of the findings of the previous studies 
and addressed the methodological limitations noted in them. 
 
Though the link between splenectomy and venous 
thromboembolic events has been explored [20–22] and 
hypothesized to be due to a hyper-coagulable state, the link 
between splenectomy and arterial events had not been fully 
explored. Therefore, the authors believe this is the first study to 
identify that individuals who have undergone a splenectomy 
appear to be at an adjusted significantly increased risk of 
developing CVD (adjusted IRR 1·69; CI 95% 1·22-2·34, 
P=0·001), even greater than the risk for those who have not 
undergone a splenectomy procedure. 
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Study Limitations: 
 
The findings of this study should be interpreted in context of its 
limitations, some of which are inherent to this design of study. 
The THIN database is populated using clinical codes classified 
by General Practitioners (GPs) following consultations with 
individuals. Therefore, the validity of the coding will be 
affected by the coding practices of individuals with some 
patients being misclassified. Every effort was taken to 
overcome this by selecting a list of multiple clinical codes for 
ITP and splenectomy to ensure every coding combination was 
taken into consideration. We did not account for the severity of 
the disease which may have given further insight. This may 
have affected the splenectomy sub-group analysis as 
individuals who have undergone splenectomy will generally 
have a more severe form of ITP which in turn could have 
increased their risk of developing CVD outcomes. The aims of 
this study were to identify associations rather than causality due 
to the nature of data being analyzed. However, this study has 
not only been able to demonstrate some important associations 
regarding ITP and CVD, it has shown that patients who have 
had splenectomy as a consequence of ITP may be at increased 
risk of CVD. On the other hand, when communicating risks to 
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patients or the public, caution is advised given the absolute risk 
difference in this young studied population (Median age 48·5 
years) with a median follow up of 5·6 years, was notably low 
(3 per 1,000 person years).  
 
Conclusion: 
 
Our study shows there is an association between ITP and an 
increased risk of developing CVD. Secondly the study shows a 
strong association with the increased risk of developing CVD 
in ITP patients who underwent a splenectomy. Physicians 
should routinely evaluate for cardiovascular symptoms and 
manage risk factors for cardiovascular disease optimally in 
patients with ITP. Decision on offering splenectomy to patients 
with ITP should take into consideration future increased risk of 
cardiovascular disease. Further research utilizing ITP registries 
and cohorts in other countries are needed confirm the risk 
observed in our study. Mechanisms that promote 
cardiovascular disease in ITP patients should be further studied 
in a laboratory setting.  
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